ALK and hematologic disorder: Our review summarizes the biology, diagnostic approach, therapeutic options, resistance mechanisms, and novel strategies for management of ALK-aberrant malignancies, with a particular emphasis on cancers beyond NSCLC, and the potential for viewing aberrant ALK as a tumor-agnostic target (including for both solid tumors and hematologic malignancies and for both common and uncommon cancers across the age spectrum).